Kiora Pharmaceuticals: Global KIO-301 Partnerships and Advancing ABACUS-2 Study Support Buy Rating with Unchanged $12 Price TargetTip Ranks·Aug 21 at 10:35 AMKPRX+3.38%
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation | KPRX Stock NewsStockTitan·Aug 18 at 10:00 PMKPRX+3.38%03121+0.79%
Jasper Therapeutics Q2 FY26 net loss narrows to $2.76 million; R&D expense drops to $5.14 millionPUBT·Aug 14 at 10:00 AMJSPR+0.89%KPRX+3.38%
Kiora Pharmaceuticals reports Q2 2026 net loss of $2.08M, cash and short-term investments $16.8MTradingView·Aug 7 at 06:13 AMKPRX+3.38%
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update | KPRX Stock NewsStockTitan·Aug 6 at 10:00 PMKPRX+3.38%
10:31 ETComplement 3 Glomerulopathy Market Set for Transformation: 4 Emerging Therapies Leading the Next Growth Phase | DelveInsightprnewswire·Jul 16 at 09:31 AMKPRX+3.38%ARWR-0.44%
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium | KPRX Stock NewsStockTitan·Jul 1 at 10:00 PMKPRX+3.38%
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model | KPRX Stock NewsStockTitan·Jun 17 at 10:00 PMKPRX+3.38%
